Clinical Trial

Latent Tuberculosis in Type 2 Diabetes

Study acronym: TB
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.
Trial Details
NCT Number NCT06874725
Lead Sponsor Taichung Veterans General Hospital
Conditions Latent Tuberculosis Infection
Enrollment 552 participants
Start Date 2018-04-18
Primary Completion 2024-04-30 (estimated)
Study Completion 2025-04-18 (estimated)
Updated on ClinicalTrials.gov 2025-03-13